Coreline Soft announced that it has completed the reapproval process with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its AI-based imaging analysis software, AVIEW. The latest approval includes the addition of new functionalities—NeuroCT and LungCT—enhancing the software’s capabilities in intracranial hemorrhage analysis and pulmonary nodule detection.
NeuroCT offers automatic analysis and visualization of suspected intracranial hemorrhages on head and neck CT scans. This feature supports rapid diagnosis in emergency situations by providing decision-support information to clinicians.
LungCT enables precise analysis of lung nodules on chest CT scans, quantifying their size, shape, and changes over time. This functionality plays an especially important role in early lung cancer detection and follow-up evaluations.
A key achievement of this approval is the expanded application of the ‘Imaging Diagnostic Management Reimbursement 3’ coding, which allows medical institutions in Japan to receive additional payments for advanced AI imaging diagnostic systems. This policy significantly incentivizes the adoption of AI solutions by offering direct reimbursement benefits, thereby promoting greater market penetration.
Japan is considered a high-entry barrier market for AI imaging solutions, owing to stringent approval and reimbursement standards. Therefore, this achievement not only demonstrates AVIEW NeuroCAD’s technical excellence but also its clinical validity, reinforcing its position within the Japanese market.
In March, Coreline Soft transferred the technology of Vuno Med–LungCT, an AI-based pulmonary nodule detection and analysis solution, from Vuno. This move, together with their existing AVIEW LCS Plus, has strengthened the company’s portfolio in thoracic imaging AI. This integration aims to secure a competitive edge and expand product trust and options within Japan.
CEO Jin Kook Kim stated, “With this approval and reimbursement expansion, we will continue to develop optimized diagnostic workflows centered on lung and brain hemorrhage detection, further strengthening our competitiveness in the Japanese healthcare market.”
Coreline Soft is scheduled to participate in the Japan Society of Thoracic Radiology (JSTR) conference on August 2nd at Shinagawa Intercity Hall in Tokyo, further demonstrating its commitment to expanding in the Japanese market.
